Content available at: https://www.ipinnovative.com/open-access-journals

IP International Journal of Ocular Oncology and Oculoplasty

Journal homepage: https://www.ijooo.org/

Review Article

Advancements in artificial intelligence for ocular oncology: Enhancing diagnostic accuracy and prognostic capabilities in eye tumors

Ankit Sanjay Varshney[1]*, Debanjali Bhattacharjee[2]

[1]Dept. of Optometry, Veer Narmad South Gujarat University, Surat, Gujarat, India
[2]Dept. of Optometry, Manipal Tata Medical College, Jamshedpur, Jharkhand, India

Abstract

Background: Ocular tumors, including uveal melanoma, retinoblastoma, and other rare neoplasms, present significant diagnostic and therapeutic challenges. Early and accurate diagnosis is vital for optimizing outcomes and improving survival rates.
Objective: This narrative review explores the applications of artificial intelligence (AI) in ocular oncology, emphasizing its role in enhancing diagnostic accuracy, risk stratification, and personalized treatment planning.
Materials and Methods: A systematic literature search was conducted across databases such as PubMed, Scopus, and Embase to identify studies published from 2010 to 2024. Key AI techniques, including convolutional neural networks (CNNs), deep learning (DL), and radiomics, were examined, along with their integration into imaging modalities such as optical coherence tomography (OCT) and fundus photography.
Results: AI tools demonstrated high accuracy in distinguishing uveal melanoma from benign nevi (87.6%) and early-stage retinoblastoma detection with sensitivity and specificity rates over 90%. Radiomics facilitated risk stratification by extracting quantitative tumor features. Hyperspectral imaging combined with AI showed promise in detecting less common ocular tumors. However, ethical concerns, data heterogeneity, and a lack of standardized imaging protocols pose barriers to clinical adoption.
Conclusion: AI holds transformative potential for ocular oncology, offering accurate, efficient, and personalized diagnostic solutions. Addressing challenges such as data quality, ethical compliance, and model generalizability through interdisciplinary collaboration is essential to fully realize its clinical impact.

Keywords: Artificial intelligence, Ocular oncology, Uveal melanoma, retinoblastoma, Deep learning, Radiomics, Diagnostic imaging, Personalized medicine.

Received: 03-12-2024; **Accepted:** 14-04-2025; **Available Online**: 31-05-2025

1. Introduction

Ocular tumors encompass a diverse and complex group of neoplasms affecting the eye and its surrounding structures, with early diagnosis playing a crucial role in patient outcomes. Uveal melanoma, the most common primary intraocular malignancy in adults, has an incidence of approximately 5.1 cases per million annually. Its aggressive nature and high risk of metastasis, particularly to the liver, contribute to a poor prognosis, with a five-year survival rate of less than 15% in metastatic cases.[1] Similarly, retinoblastoma, a rapidly progressing pediatric eye cancer, occurs primarily in children under five years of age, with a global incidence of approximately 1 in 15,000 to 20,000 live births. Timely detection of retinoblastoma is essential for improving survival rates and preserving vision, highlighting the importance of early and accurate diagnosis in ocular oncology.[2]

Traditional diagnostic methods for ocular tumors utilize imaging techniques such as optical coherence tomography (OCT), ultrasonography, fundus photography, and advanced modalities like magnetic resonance imaging (MRI) and computed tomography (CT). Although histopathological examination remains the gold standard for a definitive diagnosis, these approaches are often time-consuming, resource-intensive, and require specialized expertise. In resource-limited settings, these challenges can lead to delays

*Corresponding author: Ankit Sanjay Varshney
Email: ankitsvarshney@yahoo.com

http://doi.org/10.18231/j.ijooo.2025.005

in diagnosis, potentially compromising timely intervention and patient outcomes.[3]

Artificial intelligence (AI) is transforming ocular oncology by enhancing medical imaging and diagnostics through machine learning (ML), deep learning (DL), and convolutional neural networks (CNNs). These technologies analyze complex datasets, identifying subtle patterns that may be undetectable to the human eye. CNNs, for example, have demonstrated diagnostic accuracies exceeding 90% in distinguishing ocular lesions, facilitating the early detection of conditions such as uveal melanoma and retinoblastoma. By improving diagnostic speed, reducing variability in interpretation, and enhancing overall accuracy, AI holds significant potential to revolutionize ocular tumor detection and management.[4]

Recent advancements in AI have expanded its role in ocular oncology beyond diagnosis to include prognostication and treatment planning. Radiomics, an AI-driven technique, analyzes high-dimensional imaging features to assess tumor characteristics, aiding in metastatic risk evaluation and personalized therapeutic strategies. Deep learning (DL) models have also shown high sensitivity and specificity in early detection and stage classification, particularly in pediatric oncology for retinoblastoma. These innovations enhance clinical decision-making, enabling more precise and individualized patient care.[5]

Despite these promising advancements, challenges remain. Issues related to data quality, lack of standardized imaging protocols, and ethical concerns such as patient privacy and AI transparency hinder widespread adoption. The scarcity of large, annotated datasets further limits the generalizability of AI models, underscoring the need for interdisciplinary collaboration to develop robust, clinically validated AI systems.[6]

As the global burden of ocular tumors rises, particularly in low- and middle-income countries with limited access to specialized care, AI presents a transformative solution. By facilitating remote diagnostics, optimizing clinical workflows, and enabling early detection, AI has the potential to significantly improve patient outcomes worldwide.[7] Its real-world applications are already enhancing diagnostic accuracy and expanding access to advanced care. This review examines the evolving role of AI in ocular oncology, discussing its current applications, challenges, and future directions in research and clinical practice. **Figure 1** illustrates this progress with a line graph showing the growth of AI-related publications in ocular oncology from 2010 to 2024.

2. Materials and Methods

2.1. Study design

This narrative review explores the role of artificial intelligence (AI) in ocular oncology, with a focus on its advancements in diagnosis and prognosis. Unlike systematic reviews, it takes a thematic and analytical approach to provide a comprehensive understanding of AI's impact on detecting and managing ocular tumors, including uveal melanoma and retinoblastoma.

2.2. Literature search strategy

A thorough literature search was conducted across multiple electronic databases, including PubMed, Scopus, Web of Science, Embase, and Google Scholar. The search strategy employed Boolean operators and keywords such as *artificial intelligence*, *ocular tumors*, *uveal melanoma*, *retinoblastoma*, *radiomics*, *machine learning*, *deep learning*, and *convolutional neural networks (CNNs)*. To capture the most recent advancements, the search period spanned January 2010 to January 2024. Reference lists from selected studies were also screened for additional relevant articles.

2.3. Eligibility criteria

Inclusion criteria focused on original research articles that explored AI techniques in ocular tumor diagnosis and prognosis. Only studies involving imaging modalities such as optical coherence tomography (OCT), fundus imaging, magnetic resonance imaging (MRI), and computed tomography (CT) were considered. Studies had to report performance metrics like accuracy, sensitivity, specificity, and the area under the curve (AUC). Peer-reviewed articles published in English were included, while reviews, editorials, conference abstracts, case reports, and studies with incomplete datasets were excluded.

2.4. Study selection process

The initial database search identified 903 articles. After duplicate removal, 718 unique articles remained. Screening of titles and abstracts narrowed this down to 120 potentially relevant studies. Following a thorough full-text review, 37 high-quality studies that met all inclusion criteria were selected. The entire selection process is summarized in **Figure 2**, which presents a flow diagram visualizing the systematic progression from the initial identification of articles to the final selection of studies.

2.5. Data extraction

A standardized data extraction protocol was followed. Key information such as author, year, study location, sample size, AI methodologies, imaging modalities, and performance metrics were recorded. The strengths, limitations, and main findings of each study were documented. Two independent reviewers performed data extraction, with discrepancies resolved through discussion or consultation with a third reviewer to minimize bias.

2.6. Quality assessment

The quality of the included studies was evaluated using the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool. This assessment focused on four critical domains: patient selection, index test methodology, reference standards, and the flow and timing of data collection. To ensure reliable conclusions, only studies demonstrating robust methodological rigor were prioritized. **Figure 3** provides an illustration of the QUADAS-2 tool, highlighting its emphasis on these key evaluation domains.

2.7. Data synthesis and analysis

Given the heterogeneity in study designs and AI methodologies, a narrative synthesis was employed. Performance metrics such as accuracy, sensitivity, and specificity were aggregated and presented in summary tables. Visual tools, including bar charts comparing AI performance with traditional methods and pie charts illustrating imaging modality usage, were incorporated to enhance interpretability and highlight key findings.

2.8. Ethical considerations and limitations

This review used secondary data from published studies, ensuring proper citation and adherence to copyright guidelines. Ethical considerations included compliance with data privacy regulations, as no new patient data were collected. However, the narrative review design precluded quantitative meta-analysis, limiting the ability to generalize findings.

3. Discussion

3.1. Applications of artificial intelligence in ocular tumor diagnosis

Artificial intelligence (AI) has become a transformative force in ocular oncology, revolutionizing the diagnosis, management, and treatment of ocular tumors. Utilizing advanced computational techniques such as deep learning (DL) and machine learning (ML), AI systems are redefining diagnostic precision, minimizing human error, and enabling personalized therapeutic strategies.[8,9] This section delves into the applications of AI in diagnosing three main categories of ocular tumors: uveal melanoma, retinoblastoma, and other neoplasms, emphasizing the methodologies employed and their clinical relevance. **Figure 4** provides a pie chart illustrating the distribution of studies by tumor type, highlighting the dominance of research on uveal melanoma and retinoblastoma, while less common tumors, such as ocular surface squamous neoplasia (OSSN), receive comparatively limited focus.

3.2. Uveal melanoma

Uveal melanoma is the most common primary intraocular malignancy in adults, characterized by its potential for aggressive metastasis, particularly to the liver. Accurate differentiation between uveal melanoma and benign choroidal nevi is critical for early intervention and improved patient outcomes.[10] Convolutional Neural Networks (CNNs) have demonstrated high efficacy in distinguishing uveal melanoma from benign lesions, achieving diagnostic accuracies exceeding 87% in some studies.[11] These models analyze complex morphological features such as tumor size, asymmetry, and pigmentation that may be challenging for human observers.

Beyond initial diagnosis, AI-driven radiomics has revolutionized risk stratification in uveal melanoma. Radiomics extracts high-dimensional data from imaging modalities, quantifying tumor heterogeneity, texture, and shape. These features correlate strongly with metastatic potential, providing clinicians with valuable insights for personalized treatment planning. For instance, radiomics-based models can predict liver metastases with greater accuracy, enabling timely interventions such as targeted therapies or liver monitoring.[12,13]

Additionally, AI supports therapeutic monitoring by assessing changes in tumor characteristics over time, facilitating adaptive treatment strategies. This integration of AI into clinical workflows enhances both diagnostic precision and therapeutic efficacy, leading to better prognostic outcomes.[14,15]

3.3. Retinoblastoma

Retinoblastoma, a rare but aggressive pediatric ocular tumor, primarily affects children under the age of five. Early detection is crucial to improve survival rates and preserve visual function. Deep Learning (DL) models, including CNNs, have achieved remarkable sensitivity and specificity rates exceeding 90% in the early detection and staging of retinoblastoma.[2] These models analyze imaging data from modalities such as fundus photography and optical coherence tomography (OCT), providing rapid and accurate tumour classification.

Segmentation is another critical area where AI excels. Automated segmentation tools delineate tumor boundaries with precision, allowing for accurate calculation of tumor volume and other critical parameters.[16] This information is essential for tailoring treatment strategies, such as determining the appropriate chemotherapy dosage or planning focal therapies like laser photocoagulation and cryotherapy. By reducing manual effort and variability, AI ensures consistency in tumor assessments across different clinicians and institutions.[17]

3.4. Other ocular neoplasms

AI's applicability extends beyond uveal melanoma and retinoblastoma to other, less common ocular tumors. For example, Ocular Surface Squamous Neoplasia (OSSN) is an ocular surface malignancy that is often difficult to diagnose using traditional methods. When combined with AI algorithms, hyperspectral imaging offers a non-invasive solution. These models analyze spectral data to accurately detect early-stage malignancies, potentially reducing the need for invasive biopsy procedures.[18]

For metastatic ocular tumors, radiomics plays a vital role in distinguishing primary intraocular tumors from secondary (metastatic) lesions. By examining features such as texture, intensity, and shape across various imaging modalities, radiomics provides clinicians with detailed insights that inform targeted therapeutic strategies. This approach is particularly useful in customizing treatment for patients with systemic cancers that have metastasized to the eye.[19,20]

AI models have shown significant improvements over traditional diagnostic methods in detecting ocular tumors. **Figure 5** illustrates how AI-based systems outperform traditional techniques in distinguishing malignant tumors from benign conditions, such as uveal melanoma and retinoblastoma. Additionally, **Figure 6** presents a bar chart comparing the diagnostic performance metrics (accuracy, sensitivity, specificity) of AI versus traditional methods.

3.5. Key AI techniques in ocular oncology

AI technologies employ a spectrum of techniques that enhance diagnostic precision and prognostic accuracy in ocular oncology. The most impactful among these are:

3.6. Critical evaluation of AI models

AI models, particularly convolutional neural networks (CNNs) and deep learning (DL) systems, have demonstrated strong performance in controlled environments. However, their clinical application often falls short due to overfitting and dependence on high-quality, annotated datasets. Overfitting occurs when models become too tailored to training data, reducing their effectiveness on new or diverse datasets.[21,22]

For example, studies show that models trained on high-resolution, well-processed images struggle when applied to lower-quality or heterogeneous clinical data.[23,24] This discrepancy underscores the need for robust validation across multiple institutions and populations. Future efforts should focus on enhancing model robustness through methods such as transfer learning, data augmentation, and cross-institutional validation. These approaches can improve the generalizability of AI models, ensuring consistent performance in diverse clinical scenarios.



Figure 1: Line graph illustrating the growth in AI-related publications in ocular oncology from 2010 to 2024.



Figure 2: Flow diagram visualizing the systematic literature selection process, from the initial identification of articles to the final selection of included studies.



Figure 3: Illustration of the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool, emphasizing evaluation across four key domains: patient selection, index test methodology, reference standards, and the flow and timing of data collection.



Figure 4: Pie chart illustrating the distribution of studies by tumor type, with a clear emphasis on the predominance of research focused on uveal melanoma and retinoblastoma.



Figure 5: Bar chart comparing the performance of AI models with traditional methods, showing substantial improvements in the diagnosis of various ocular tumors.



Figure 6: Bar chart comparing the diagnostic performance metrics (accuracy, sensitivity, specificity) of AI versus traditional methods.

Imaging modalities are crucial in AI applications for ocular oncology. **Figure 7** illustrates the distribution of imaging techniques used in research, with optical coherence tomography (OCT) and magnetic resonance imaging (MRI) being the most prevalent. **Figure 8** presents a network diagram mapping the relationships between AI techniques (e.g., CNNs, deep learning, radiomics) and imaging modalities (e.g., OCT, MRI).

3.7. Ethical concerns and patient privacy

The "black box" nature of AI—where decision-making processes are opaque—represents a major barrier to clinical adoption. Both clinicians and patients are often hesitant to trust systems that lack clear interpretability.[25] Explainable AI (XAI) frameworks address this challenge by providing transparent, human-readable explanations for AI decisions, thus enhancing trust and enabling clinicians to validate AI outputs in the clinical context.[26]



Figure 7: Pie chart showing the distribution of imaging modalities used in AI-based ocular oncology research, with OCT and MRI being the most prevalent.



Figure 8: Network diagram mapping the relationships between AI techniques (e.g., CNNs, deep learning, radiomics) and imaging modalities (e.g., OCT, MRI).



Figure 9: Bar chart summarizing the challenges (e.g., data heterogeneity, ethical issues) and their significance in advancing AI in ocular oncology.

Additionally, compliance with data protection regulations, such as the General Data Protection Regulation

(GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, is essential. These regulations enforce strict measures to protect patient data. AI developers must implement data anonymization, secure storage, and restricted access to ensure compliance and maintain patient confidence in AI systems.[27] **Figure 9** presents a bar chart summarizing the challenges (e.g., data heterogeneity, ethical issues) and their importance in advancing AI in ocular oncology.

Additionally, restricting the review to English-language studies may have excluded valuable research from non-English sources. These limitations are acknowledged, and future systematic reviews are recommended for more comprehensive evaluations.

3.8. Dataset diversity and generalizability

AI models trained on homogeneous datasets often exhibit poor generalizability when applied to diverse populations. This limitation can lead to biases and reduced accuracy in underrepresented groups. For example, differences in imaging modalities, patient demographics, and disease presentation across institutions can compromise model performance.[28]

To overcome this challenge, the development of global datasets that encompass a broad range of demographics and imaging conditions is crucial. Federated learning offers a promising solution by enabling collaborative model training across multiple institutions without sharing raw patient data. This approach preserves privacy while enhancing model robustness and generalizability.[29]

3.9. Broadening performance metrics beyond accuracy

Traditional performance metrics, such as accuracy, sensitivity, and specificity, are important but insufficient for evaluating AI systems comprehensively. Real-world clinical environments require a broader set of metrics, including:

3.9.1. False positive/Negative rates

To understand the risk of misdiagnosis.

3.9.2. Robustness

The ability of AI models to maintain performance across varied and noisy datasets.

3.9.3. Clinical relevance

The practical utility of AI predictions in improving patient outcomes.

Real-world studies have demonstrated that AI systems may perform inconsistently when exposed to new data sources or environments. By incorporating these additional metrics, researchers can better assess AI's clinical readiness and reliability.[30]

3.10. Implementation strategies in clinical practice

Successful integration of AI into clinical practice requires a systematic and phased approach:

3.10.1. Pilot programs

Initial deployment in controlled settings to evaluate feasibility and impact. These programs help identify potential challenges and refine AI tools before broader adoption.

3.10.2. Clinician training programs

Educating healthcare providers on interpreting AI outputs and incorporating them into clinical workflows is essential. This step bridges the gap between AI insights and clinical decision-making.

3.10.3. Infrastructure enhancements

Upgrading healthcare IT systems to accommodate AI technologies, including computational power, data storage, and interoperability with electronic health records (EHRs). This is particularly crucial in resource-limited settings, where infrastructure gaps can hinder AI deployment.[31,32,33,34]

3.11. Future research directions

3.11.1. Data augmentation and diversity

AI models must overcome biases from homogeneous datasets by utilizing diverse, heterogeneous datasets encompassing various ethnicities and imaging conditions. Techniques like synthetic data generation (e.g., GANs) and federated learning are pivotal for improving model robustness while preserving privacy.

3.11.2. Explainable AI (XAI)

To enhance clinical trust, XAI frameworks should provide transparent, human-readable insights into AI decision-making. This includes feature importance analysis and visual explanations to support regulatory and clinical acceptance.

3.11.3. Real-time AI integration

Integrating AI with Electronic Health Records (EHRs) allows for dynamic, personalized treatment planning. Such integration provides contextual insights and real-time alerts, improving decision-making and patient care efficiency.

3.11.4. Longitudinal studies

Long-term studies are essential to assess AI's sustained impact on patient outcomes, including survival rates, quality of life, and healthcare costs. These studies will also evaluate model adaptability to evolving clinical practices and technologies.

4. Conclusion

Artificial intelligence (AI) is transforming ocular oncology by improving the detection, classification, and management of eye tumors such as uveal melanoma and retinoblastoma with high accuracy. By leveraging deep learning and advanced imaging techniques, AI enables early diagnosis and personalized treatment planning, leading to better patient outcomes. However, challenges such as the need for high-quality data, transparency in AI decision-making, and data privacy concerns must be addressed. Solutions include developing diverse datasets, implementing explainable AI, and adopting secure data-sharing methods. Integrating AI with electronic health records can further enhance real-time decision-making and streamline clinical workflows. To fully realize its potential, interdisciplinary collaboration among clinicians, researchers, and policymakers is essential to ensure AI tools are reliable, ethical, and beneficial for patient care.

5. Ethical Approval

As this is a narrative review article based on existing literature; ethical approval was not required. All data and studies referenced were previously published and publicly available.

6. Source of funding

None.

7. Conflict of interest

There are no conflicts of interest

References

1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. *Eye (Lond)*. 2017;31(2):241–57.
2. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. Retinoblastoma. *Orphanet J Rare Dis*. 2006;1:31.
3. Aumann S, Donner S, Fischer J. Optical coherence tomography (OCT): principle and technical realization. In: Bille JF, editor. High Resolution Imaging in Microscopy and Ophthalmology: New Frontiers in Biomedical Optics [Internet]. Cham (CH): Springer; 2019. Chapter 3. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554044/ doi:10.1007/978-3-030-16638-0_3
4. Najjar R. Redefining radiology: a review of artificial intelligence integration in medical imaging. *Diagnostics (Basel)*. 2023;13(17):2760.
5. Zhang YP, Zhang XY, Cheng YT, Bing L, Xin-Zhi T, Jiang Z, et al. Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling. *Mil Med Res*. 2023;10(1):22.
6. Zuhair V, Babar A, Ali R, et al. Exploring the impact of artificial intelligence on global health and enhancing healthcare in developing nations. *J Prim Care Community Health*. 2024;15:21501319241245847.
7. Institute of Medicine (US) Committee on Cancer Control in Low- and Middle-Income Countries; Sloan FA, Gelband H, editors. Cancer Control Opportunities in Low- and Middle-Income Countries. Washington (DC): National Academies Press (US); 2007. Available from: https://www.ncbi.nlm.nih.gov/books/NBK54028/
8. Koseoglu ND, Corrêa ZM, Liu TYA. Artificial intelligence for ocular oncology. *Curr Opin Ophthalmol*. 2023;34(5):437–40.
9. Vempuluru VS, Viriyala R, Ayyagari V, Komal B, Patanjali B, Krishna KD, et al. Artificial intelligence and machine learning in ocular oncology, retinoblastoma (ArMOR): experience with a multiracial cohort. *Cancers (Basel)*. 2024;16(20):3516.
10. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multigene expression assay for predicting metastasis in uveal melanoma. *J Mol Diagn*. 2010;12(4):461–8.
11. Krantz BA, Dave N, Komatsubara KM, Brian PM, Richard DC. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. *Clin Ophthalmol*. 2017;11:279–89.
12. Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. *Nat Rev Clin Oncol*. 2022;19(2):132–46.
13. Tomaszewski MR, Gillies RJ. The biological meaning of radiomic features. *Radiology*. 2021;298(3):505–16.
14. Liu TYA, Zhu H, Chen H, Arevalo JF, Hui FK, Yi PH, et al. Gene expression profile prediction in uveal melanoma using deep learning: a pilot study for the development of an alternative survival prediction tool. *Ophthalmol Retina*. 2020;4:1213–5.
15. Liu TYA, Chen H, Gomez C, Correa ZM, Unberath M. Direct gene expression profile prediction for uveal melanoma from digital cytopathology images via deep learning and salient image region identification. Ophthalmol Sci. 2023;3(1):100240.
16. Strijbis VIJ, de Bloeme CM, Jansen RW, Kebiri H, Huu-Giao N, Jong MC, et al. Multiview convolutional neural networks for automated ocular structure and tumor segmentation in retinoblastoma. *Sci Rep*. 2021;11:14590.
17. Byroju VV, Nadukkandy AS, Cordani M, Lekha DK. Retinoblastoma: present scenario and future challenges. *Cell Commun Signal*. 2023;21(1):226.
18. Sinha S, Ramesh PV, Nishant P, Morya AK, Prasad R. Novel automated non-invasive detection of ocular surface squamous neoplasia using artificial intelligence. *World J Methodol*. 2024;14(2):92267.
19. Augsburger JJ, Corrêa ZM, Trichopoulos N, Shaikh A. Size overlap between benign melanocytic choroidal nevi and choroidal malignant melanomas. *Invest Ophthalmol Vis Sci*. 2008;49:2823–8.
20. Zabor EC, Raval V, Luo S, David EP, Arun DS. A prediction model to discriminate small choroidal melanoma from choroidal nevus. *Ocul Oncol Pathol*. 2022;8(1):71–8.
21. Alzubaidi L, Zhang J, Humaidi AJ, Ye D, Al-Shamma O, Santamaría J, et al. Review of deep learning: concepts, CNN architectures, challenges, applications, future directions. *J Big Data*. 2021;8(1):53. https://doi.org/10.1186/s40537-021-00444-8
22. Chen YN, Wang YN, Chen MX, Zhang K, Rong-Tian C, Rui F, et al. Machine learning models for outcome prediction of Chinese uveal melanoma patients: a 15-year follow-up study. *Cancer Commun (Lond)*. 2022;42(3):273–6.
23. Li M, Jiang Y, Zhang Y, Zhu H. Medical image analysis using deep learning algorithms. *Front Public Health*. 2023;11:1273253. https://doi.org/10.3389/fpubh.2023.1273253
24. Pinto-Coelho L. How artificial intelligence is shaping medical imaging technology: a survey of innovations and applications. *Bioengineering (Basel)*. 2023;10(12):1435.
25. Rai A. Explainable AI: from black box to glass box. *J Acad Mark Sci*. 2019;48:137–41.
26. Adeniran A, Onebunne A, William P. Explainable AI (XAI) in healthcare: enhancing trust and transparency in critical decision-making. *World J Adv Res Rev*. 2024;23(3)2647–58.
27. Shuaib M, Alam S, Alam M, Nasir M. Compliance with HIPAA and GDPR in blockchain-based electronic health records. *Mater Today Proc*. 2021. https://doi.org/10.1016/j.matpr.2021.03.059
28. Wang Y, Yao Q, Kwok JT, et al. Generalizing from a few examples: a survey on few-shot learning. *ACM Comput Surv* (CSUR). 2020;53:1–34.
29. Zhang H, Liu Y, Zhang K, Shiqi H, Yu F, Jingting L, et al. Validation of the relationship between iris color and uveal melanoma using artificial intelligence with multiple paths in a large Chinese population. *Front Cell Dev Biol*. 2021;9:713209.
30. Yin J, Ngiam KY, Teo HH. Role of artificial intelligence applications in real-life clinical practice: systematic review. *J Med Internet Res*. 2021;23(4):e25759. https://doi.org/10.2196/25759
31. Luo J, Chen Y, Yang Y, Kai Z, Yueming L, Hanqing Z, et al. Prognosis prediction of uveal melanoma after plaque brachytherapy

based on ultrasound with machine learning. *Front Med (Lausanne)*. 2021;8:777142.

32. Donizy P, Krzyzinski M, Markiewicz A, Pawel K, Krzysztof K, Artur K, et al. Machine learning models demonstrate that clinicopathologic variables are comparable to gene expression prognostic signature in predicting survival in uveal melanoma. *Eur J Cancer*. 2022;174:251–60.
33. Yoo TK, Choi JY, Kim HK, et al. Adopting low-shot deep learning for the detection of conjunctival melanoma using ocular surface images. *Comput Methods Programs Biomed*. 2021;205:106086.
34. Corrêa ZM, Augsburger JJ. Indications for fine needle aspiration biopsy of posterior segment intraocular tumors. *Am J Ophthalmol*. 2019;207:45–61.

Cite this article Varshney AS, Bhattacharjee D. Advancements in artificial intelligence for ocular oncology: Enhancing diagnostic accuracy and prognostic capabilities in eye tumors. *IP Int J Ocul Oncol Oculoplasty*. 2025;11(1):22-29.